FDA’s vaccine advisers on Friday (Sept. 17) voted 18-0 in favor of granting emergency use authorization to a third dose, or booster, of Pfizer’s two-dose COVID-19 vaccine for those 65 and older or at high risk of illness, coming after the advisory committee voted overwhelmingly against approving boosters for people ages 16 and up. FDA initially asked members of its Vaccines and Related Biological Products Advisory Committee to vote on whether the data support approving boosters of Pfizer’s vaccine for...